跳到正文
AiSeekAiSeek
登录
新出现医疗健康报道时间 2026-10-07 19:00

Armata Pharmaceuticals 通过两项最近获得的美国专利加强了知识产权组合

Armata Pharmaceuticals 获得了其溶菌酶项目 AP-SA02 和 AP-PA02 的两项新的美国专利，保护期延长至至少 2041 年。

为什么重要. Armata 的加强知识产权组合增强了其在细菌噬菌体治疗领域的竞争地位，保护其领先候选药物，并可能延缓竞争对手的进入。

01

影响到谁

  1. 1Armata Pharmaceuticals
  2. 使用 →事实
    2bacteriophage-based technology技术
02

证据

  • PPR Newswire news releases公司披露2026-10-07 19:00
    using its proprietary bacteriophage-based technology
    查看来源
  • PPR Newswire news releases公司披露2026-10-07 19:00
    the company's global IP portfolio consists of 101 issued patents (15 U.S. and 86 ex-U.S.) and 60 pending patent applications (9 U.S. and 51 ex-U.S.) with nominal expiration dates through 2046.
    查看来源
  • PPR Newswire news releases公司披露2026-10-07 19:00
    Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041
    查看来源
  • PPR Newswire news releases公司披露2026-10-07 19:00
    These newly issued U.S. patents support Armata's leadership in bacteriophage therapeutics and specifically, strengthen the intellectual property ("IP") around the AP-SA02 and AP-PA02 programs, which are highly impactful and potential first- and best-in-class therapies. With pate…
    查看来源
  • PPR Newswire news releases公司披露2026-10-07 19:00
    Issued on October 6, 2026, protects methods of treating Staphylococcus aureus infections using its lead product candidate, AP-SA02, which is currently in development for adjunct treatment of complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S.…
    查看来源